Financials Newron Pharmaceuticals S.p.A.

Equities

Market Closed - Swiss Exchange Other stock markets 11:31:47 2024-06-25 EDT			5-day change	1st Jan Change
9.56 ^CHF	-12.77%		-9.98%	+93.13%

05-13	Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients	CI
04-30	Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	104.4	35.36	27.92	27.93	95.03	186.1	-	-
Enterprise Value (EV) ¹	81.95	29.79	27.92	60.17	114.8	208.1	179.1	161.1
P/E ratio	-5.18 x	-1.68 x	-1.86 x	-1.6 x	-5.85 x	11.9 x	34 x	7.83 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	14.8 x	6.73 x	4.85 x	4.58 x	10.5 x	5.03 x	6.89 x	4.36 x
EV / Revenue	11.6 x	5.67 x	4.85 x	9.87 x	12.7 x	5.63 x	6.63 x	3.78 x
EV / EBITDA	-3.96 x	-1.67 x	-2.3 x	-4.59 x	-10 x	10.5 x	17.9 x	5.55 x
EV / FCF	-3.68 x	-1.91 x	-	-5.42 x	-11.3 x	7.28 x	13.2 x	5.24 x
FCF Yield	-27.2%	-52.4%	-	-18.5%	-8.84%	13.7%	7.59%	19.1%
Price to Book	-	2.05 x	-	-1.99 x	-3.17 x	-19.2 x	14.4 x	5.72 x
Nbr of stocks (in thousands)	17,845	17,845	17,845	17,845	17,845	18,632	-	-
Reference price ²	5.848	1.982	1.565	1.565	5.325	9.987	9.987	9.987
Announcement Date	20-03-05	21-03-16	22-03-15	23-03-14	24-03-19	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	7.038	5.258	5.762	6.094	9.057	36.98	27.02	42.65
EBITDA ¹	-20.69	-17.85	-12.15	-13.1	-11.43	19.81	9.998	29
EBIT ¹	-20.9	-18.07	-12.36	-13.3	-11.63	19.43	9.957	29
Operating Margin	-296.95%	-343.59%	-214.46%	-218.28%	-128.4%	52.54%	36.85%	68%
Earnings before Tax (EBT) ¹	-20.16	-19.62	-14.88	-17.47	-16.2	15.73	6.133	26.75
Net income ¹	-20.21	-21	-14.9	-17.49	-16.22	15.07	5.133	22.75
Net margin	-287.11%	-399.35%	-258.61%	-287.05%	-179.13%	40.75%	19%	53.34%
EPS ²	-1.130	-1.180	-0.8400	-0.9800	-0.9100	0.8400	0.2933	1.275
Free Cash Flow ¹	-22.26	-15.62	-	-11.11	-10.15	28.6	13.6	30.75
FCF margin	-316.3%	-297.11%	-	-182.31%	-112.08%	77.35%	50.33%	72.1%
FCF Conversion (EBITDA)	-	-	-	-	-	144.36%	136.03%	106.03%
FCF Conversion (Net income)	-	-	-	-	-	189.82%	264.95%	135.16%
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	20-03-05	21-03-16	22-03-15	23-03-14	24-03-19	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	32.2	19.8	22.1	-	-
Net Cash position ¹	22.4	5.58	-	-	-	-	7	25
Leverage (Debt/EBITDA)	-	-	-	-2.461 x	-1.733 x	1.113 x	-	-
Free Cash Flow ¹	-22.3	-15.6	-	-11.1	-10.2	28.6	13.6	30.8
ROE (net income / shareholders' equity)	-	-	-	-	-	-	-	143%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share ²	-	0.9700	-	-0.7900	-1.680	-0.5200	0.6900	1.750
Cash Flow per Share	-	-	-	-	-	-	-	-
Capex ¹	0.05	0.03	0.02	-	0.01	0.07	0.06	-
Capex / Sales	0.72%	0.65%	0.35%	-	0.12%	0.19%	0.2%	-
Announcement Date	20-03-05	21-03-16	22-03-15	23-03-14	24-03-19	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

D+

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.987 EUR

Average target price

14.78 EUR

Spread / Average Target

+47.94%

	1st Jan change	Capi.
NEWRON PHARMACEUTICALS S.P.A.	+93.13%	199M
CSL LIMITED	+2.72%	94.22B
SAMSUNG BIOLOGICS CO.,LTD.	-3.42%	37.76B
BIOGEN INC.	-13.75%	32.5B
UCB	+73.19%	27.75B
BIOMARIN PHARMACEUTICAL INC.	-11.88%	16.13B
INCYTE CORPORATION	+0.49%	14.19B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.95%	11.42B
ALTEOGEN INC.	+190.36%	11.06B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.07%	9.09B